Risk factors

Protalix BioTherapeutics (PLX) risk factors

Item 1A of every Protalix BioTherapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open PLX in Gloom →
Protalix BioTherapeutics' chart, financials and news, free in your browser.Open PLX in Gloom →
  • FY2025 10-K risk factors
    52 risks3 new5 dropped15 reworded

    Protalix added risks regarding Brazilian drug purchases and U.S. healthcare laws, and updated risks for Israeli military conflicts and currency exposure.

    Filed Mar 18, 2026
  • FY2024 10-K risk factors
    54 risks

    Protalix relies heavily on commercial partners Chiesi and Pfizer for revenue from its marketed products Elfabrio and Elelyso. The company faces significant manufacturing, regulatory, and collaboration risks, including a breach by its Brazilian distributor Fiocruz. Protalix holds $227.2 million in net operating loss carryforwards subject to potential ownership change limits.

    Filed Mar 17, 2025